Q&A: FDA's Pe­ter Marks ready to en­cour­age more ac­cel­er­at­ed ap­provals for rare dis­eases

FDA bi­o­log­ics cen­ter di­rec­tor Pe­ter Marks said the agency plans to en­cour­age spon­sors to use the ac­cel­er­at­ed ap­proval path­way, par­tic­u­lar­ly for rare dis­ease treat­ments, as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER